RLAYRelay Therapeutics, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but heavy debt (CCC) and big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$120.5M, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -97% · now 14% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can RLAY take a bad year?
The deepest fall in RLAY's price history on file is −97%; it is 14% below its high today.
Altman Z-score · distress below 1.8 · safe above 3 · safe zone, the balance sheet is not what threatens this one
- Annualised volatility
- 70%
Annualised volatility · three times the market's own swing
- Worst drawdown on file
- −97%
Worst drawdown on file · −14% today
Details›
- Cash and short-term investments
- $121M
- EBITDA, trailing twelve months
- −$308M
- Operating profit, trailing twelve months
- −$310M
- Annualised volatilitytwo years of daily moves
- 70%
- Worst drawdown on file
- −97%
- Below its 52-week high
- 14%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.